On June 18, 2021, the Ministry of Solidarity and Health published an Order in the Official Journal of the French Republic in relation to the innovation package (forfait innovation) for the test ONCOGRAMME aimed at predicting the effectiveness of chemotherapy with regard to non-operable metastatic colorectal cancer.
The amount of innovation package for the test ONCOGRAMME, including the coverage of the test and the associated hospital costs, is €3,125 per patient. This package can be paid in addition to the DRG tariff. ONCOGRAMME is covered under the innovation package for the period of 28 months from the beginning of the study, with the total number of patients set at 600. The list of health establishments for which health insurance covers the test is provided in the Annex to the Order.
The full details in French can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).